Group 1 - The core viewpoint of the articles highlights the performance of the CSI 300 Pharmaceutical Index, which closed at 11,931.35 points, showing a decline of 1.18% over the past month, an increase of 7.25% over the past three months, and a year-to-date increase of 9.53% [1][2] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The top ten weighted companies in the CSI 300 Pharmaceutical Index include: Heng Rui Medicine (43.14%), Pian Zai Huang (10.14%), Yunnan Baiyao (8.49%), Kelun Pharmaceutical (6.31%), East China Pharmaceutical (5.98%), New Harmony (5.69%), Fosun Pharmaceutical (5.53%), Tong Ren Tang (4.16%), Bai Li Tian Heng (3.83%), and China Resources Sanjiu (3.54%) [1] Group 2 - The market share of the CSI 300 Pharmaceutical Index is dominated by the Shanghai Stock Exchange at 69.99%, while the Shenzhen Stock Exchange accounts for 30.01% [2] - In terms of industry composition, the index is primarily made up of drug formulations at 64.78%, traditional Chinese medicine at 29.52%, and raw materials at 5.69% [2] - The index samples are adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December each year, and weights are fixed until the next scheduled adjustment [2]

Index Performance - The CSI A500 Index rose by 0.96% this week, closing at 4707.08 points on July 11, marking three consecutive weeks of gains [6] - The average daily trading volume for the week was 4067.87 billion yuan, with a week-on-week increase of 10.89% [6] Component Stocks Performance - The top ten gainers this week included: 1. Zhongyou Capital (000617.SZ) with a gain of 27.78% 2. Quzhou Development (600208.SH) with a gain of 23.67% 3. Northern Rare Earth (600111.SH) with a gain of 21.66% 4. Shenghe Resources (600392.SH) with a gain of 18.99% 5. Harbin Investment (600864.SH) with a gain of 16.36% 6. China Rare Earth (000831.SZ) with a gain of 16.31% 7. Baogang Group (600010.SH) with a gain of 15.47% 8. New Town Holdings (601155.SH) with a gain of 12.98% 9. JA Solar Technology (002459.SZ) with a gain of 12.56% 10. Sungrow Power Supply (300274.SZ) with a gain of 12.50% [4] - The top ten losers included: 1. Huahai Pharmaceutical (600521.SH) with a loss of 9.50% 2. Kelun Pharmaceutical (002422.SZ) with a loss of 8.61% 3. Baillie Gifford (688506.SH) with a loss of 8.43% 4. Junshi Biosciences (688180.SH) with a loss of 7.54% 5. Dongpeng Beverage (605499.SH) with a loss of 6.30% 6. Yingfeng Environment (000967.SZ) with a loss of 5.94% 7. Ziwen Mining (601899.SH) with a loss of 5.79% 8. Juhua Group (600160.SH) with a loss of 5.62% 9. Shandong Gold (600547.SH) with a loss of 5.41% 10. Pudong Development Bank (600000.SH) with a loss of 5.35% [4] Fund Performance - All 38 CSI A500 funds collectively rose this week, with the top performer being the Fortune Fund, which increased by 1.48% [7] - The total scale of these funds reached 1985.44 billion yuan, with the top three being Huatai-PineBridge (189.17 billion yuan), Guotai (178.43 billion yuan), and GF Fund (171.80 billion yuan) [7] Market Insights - Recent reports indicate that the A-share market has broken through key levels, moving away from a "full reduction" mindset, with structural expansion observed [8] - The bond market is experiencing low interest rates and volatility, facing strong resistance both upwards and downwards [8] - The report suggests that the second half of the year will see an influx of incremental capital, driving the market to a new level, with insurance capital leading the way [8] - The technology sector is highlighted as having high probability and return potential due to industry trends and supportive policies [8] - Consumer data shows signs of improvement, with macroeconomic indicators reflecting positive trends, particularly in discretionary consumption [9]

Group 1 - The company announced the resignation of external director Mr. Wang Guangji due to compliance with the "Management Measures for Part-time Positions of Academicians of the Chinese Academy of Engineering" [1] - Mr. Wang's resignation will not result in the board of directors falling below the legal minimum number of members and will not affect the normal operations of the company [1] - The company will promptly elect a new director in accordance with its articles of association and relevant regulations [1] Group 2 - The company commissioned a credit rating agency, United Credit Ratings Co., Ltd., to conduct a comprehensive analysis of its credit status [4] - The credit rating agency assigned the company a long-term credit rating of AAA with a stable outlook, valid from July 9, 2025, to July 8, 2026 [4]

Group 1 - The core point of the news is the performance and holdings of the China Europe Medical Health Mixed Fund C, which has shown a recent net value increase of 0.94% but a one-month return of -0.94% [1] - The fund's three-month return is 16.34%, ranking 306 out of 1238 similar funds, while its year-to-date return is 10.10%, ranking 434 out of 1218 [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed Fund C was established on September 29, 2016, and as of March 31, 2025, it has a total scale of 15.566 billion yuan [1] - The fund is managed by two key managers: Ms. Ge Lan, who has been managing it since its inception, and Ms. Zhao Lei, who took over management on July 4, 2025 [2]

证券代码：002422 证券简称：科伦药业 公告编号：2025-052 日前，联合资信在对公司生产经营状况、宏观经济和政策环境、行业发展、 重大事项、财务情况等方面进行综合分析与评估的基础上，出具了《四川科伦药 业股份有限公司主体长期信用评级报告》，评定公司主体信用等级为 AAA，评级 展望为稳定，有效期为 2025 年 7 月 9 日至 2026 年 7 月 8 日。 特此公告。 四川科伦药业股份有限公司董事会 2025 年 7 月 10 日 四川科伦药业股份有限公司 关于主体信用评级结果的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚假记载、误 导性陈述或者重大遗漏负连带责任。 四川科伦药业股份有限公司（以下简称"公司"）委托信用评级机构联合资 信评估股份有限公司（以下简称"联合资信"）对公司的信用状况进行了综合分 析。 ...

四川科伦药业股份有限公司（以下简称"公司"）董事会于近日收到外部董事 王广基先生递交的书面辞职报告，因需执行《中国工程院院士兼职管理办法》有关 兼职管理的规定，王广基先生向公司董事会申请辞去公司董事及董事会战略委员会 委员等相关职务，上述职务原定任期至第八届董事会届满之日止。王广基先生系任 期届满前辞职，其辞职报告自送达公司董事会之日起生效。辞去上述职务后，王广 基先生将不再担任公司任何职务。 王广基先生辞去董事职务后，不会导致公司董事会成员低于法定最低人数， 也不会影响公司相关工作的正常进行。公司将依据《公司章程》等有关规定尽快 补选新任董事。 截至本公告日，王广基先生未持有公司股票，不存在应当履行而未履行的承 诺事项。 特此公告。 证券代码：002422 证券简称：科伦药业 公告编号：2025-051 四川科伦药业股份有限公司 关于董事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司董事会 2025年7月10日 ...

Group 1 - The core viewpoint of the articles highlights the performance of the CSI 300 Pharmaceutical Index, which closed at 11609.22 points, showing a decline of 2.48% over the past month, an increase of 5.29% over the past three months, and a year-to-date increase of 6.57% [1] - The CSI 300 Pharmaceutical Index is composed of listed companies in the pharmaceutical sector selected from the CSI 300 Index, reflecting the overall performance of these companies [1] - The index was established on December 31, 2004, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the CSI 300 Pharmaceutical Index include: Heng Rui Medicine (41.61%), Pian Zai Huang (10.46%), Yunnan Baiyao (8.71%), Kelun Pharmaceutical (6.52%), East China Pharmaceutical (6.0%), New Harmony (5.88%), Fosun Pharmaceutical (5.59%), Tong Ren Tang (4.26%), Bai Li Tian Heng (4.09%), and China Resources Sanjiu (3.63%) [1] - The market segment distribution of the CSI 300 Pharmaceutical Index shows that the Shanghai Stock Exchange accounts for 69.26% and the Shenzhen Stock Exchange accounts for 30.74% [2] - In terms of industry composition, the index sample consists of 63.81% drug formulations, 30.31% traditional Chinese medicine, and 5.88% raw materials [2] Group 3 - The index sample is adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with the regular sample adjustments, which occur at the same time [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]

Group 1 - The core point of the article highlights the performance and holdings of the Huatai-PineBridge Healthcare Flexible Allocation Mixed Fund A, which has shown significant returns over various time frames [1] - As of July 7, 2025, the fund's latest net value is 1.7320 yuan, reflecting a decrease of 2.26% [1] - The fund's performance over the past month is a return of 0.35%, ranking 1209 out of 2349 in its category; over the past six months, it has achieved a return of 49.18%, ranking 3 out of 2317; and since the beginning of the year, it has returned 43.85%, ranking 4 out of 2315 [1] Group 2 - The top ten stock holdings of the fund account for a total of 64.17%, with significant positions in companies such as Heng Rui Medicine (10.23%), Kelun Pharmaceutical (9.09%), and Bai Li Tianheng (8.94%) [1] - The fund was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan [1] - The fund manager, Zhang Wei, has extensive experience in the pharmaceutical sector, having held various positions in research and fund management since 2021 [2]

Investment Rating - The report maintains an "Outperform" rating for A-Shares including Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, WuXi AppTec, Asymchem Laboratories, Hangzhou Tigermed Consulting, and APT Medical [6][32] - The report also maintains an "Outperform" rating for H-Shares including PATEO, Hansoh Pharmaceutical Group, Innovent Biologics, WuXi XDC Cayman, Luye Pharma Group, and BeiGene [6][32] Core Insights - The commercial insurance innovative drug list is expected to be released soon, which is anticipated to improve the domestic market significantly [33] - The National Healthcare Security Administration and National Health Commission have released measures to support the high-quality development of innovative drugs, focusing on high-innovation drugs with significant clinical value [33] - The pharmaceutical sector underperformed the market in June 2025, with the Shanghai Composite Index rising by 2.9% while the SW Pharma Bio index rose by only 0.7% [34] - The Hang Seng Healthcare sector outperformed the market with an increase of 8.4% in June 2025, while the U.S. S&P Healthcare Select Sector underperformed with a rise of only 1.9% [35] Summary by Sections - **Investment Highlights**: Continuous positive outlook for innovative drugs and industry chain, with specific A-Shares and H-Shares recommended for investment [32][6] - **Market Performance**: In June 2025, the pharmaceutical sector's performance was weak compared to the overall market, ranking 19th among Shenwan primary industries [34] - **Sub-sector Analysis**: The best-performing sub-sectors included medical services (+4.8%), chemical preparations (+0.8%), and chemical raw materials (+0.5%) [34][20] - **Stock Performance**: Top gainers in the pharmaceutical sector included Zhejiang Anglikang Pharmaceutical (+146.4%) and Hubei Huaqiang High-Tech Co., Ltd. (+67.4%), while top losers included Kexing Biopharm Co., Ltd. (-28.7%) [34][23]

Group 1 - The core viewpoint of the news is the performance and holdings of the China Europe Medical Health Mixed A Fund, which has shown a net value increase of 1.77% recently and a year-to-date return of 8.30% [1] - The fund's recent one-month return is 0.30%, with a six-month return of 8.30%, ranking 628 out of 1722 in its category for both periods [1] - The top ten stock holdings of the fund account for a total of 55.30%, with significant positions in companies such as Heng Rui Pharmaceutical (10.60%) and WuXi AppTec (9.95%) [1] Group 2 - The China Europe Medical Health Mixed A Fund was established on September 29, 2016, and has a total scale of 15.613 billion yuan as of March 31, 2025 [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at various financial institutions [2]